Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Medtronic ( (MDT) ).
On March 18, 2026, MiniMed announced early U.S. FDA clearance of the MiniMed Flex, a discreet, smartphone-controlled next-generation insulin pump, enabling earlier-than-expected commercialization of this strategically important product. The device’s development was partially funded by Blackstone Life Sciences, entitling Blackstone to royalties or minimum payments for the first two years after U.S. regulatory approval and commercial launch.
MiniMed will record a one-time $157 million charge in the fourth quarter of fiscal 2026 tied to future payments owed to Blackstone, reducing Medtronic’s Q4 fiscal 2026 earnings by about $0.08 per share, while the March 9, 2026 MiniMed IPO of a 10% stake will add an additional $0.04 per share of dilution in that quarter. Reflecting these MiniMed-related impacts, on March 24, 2026 Medtronic lowered its fiscal 2026 non-GAAP EPS guidance to $5.50–$5.54 from $5.62–$5.66, but left its fiscal 2027 outlook for high single-digit EPS growth unchanged.
The most recent analyst rating on (MDT) stock is a Buy with a $100.00 price target. To see the full list of analyst forecasts on Medtronic stock, see the MDT Stock Forecast page.
Spark’s Take on MDT Stock
According to Spark, TipRanks’ AI Analyst, MDT is a Outperform.
MDT scores well primarily on solid underlying financial performance led by strong free cash flow, reinforced by a positive earnings call with reiterated guidance and traction across key growth franchises. The score is tempered by weaker near-term technical setup (below key moving averages) and only middling valuation (P/E ~26.9), plus noted data-consistency uncertainty in the latest TTM balance sheet and margin presentation.
To see Spark’s full report on MDT stock, click here.
More about Medtronic
Medtronic plc, through its consolidated subsidiary MiniMed Group, Inc., operates in the medical technology industry with a focus on diabetes care, including insulin delivery systems. MiniMed develops insulin pumps and related technologies aimed at improving glucose management for patients, positioning Medtronic as a key player in advanced, connected diabetes therapy devices.
Average Trading Volume: 8,205,687
Technical Sentiment Signal: Hold
Current Market Cap: $111.9B
See more insights into MDT stock on TipRanks’ Stock Analysis page.